Management of Hepatitis C Infection

  • Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 1/9/21 (What's New)

Summary

  • Continuation of failing PI-based regimen promotes accumulation of additional, compensatory resistance mutations[Sarrazin 2010]
  • After PI stopped, PI-resistant HCV may decrease to baseline levels[Sarrazin 2010]
    • Rate of resistant virus “disappearance” depends on fitness of virus compared with wild-type virus

Action required

Keywords: Hepatitis C-Resistance, Hepatitis C-Treatment

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.